Cargando…

Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis

BACKGROUND: In acute decompensated heart failure, guidelines recommend increasing loop diuretic dose or adding a thiazide diuretic when diuresis is inadequate. We set out to determine the adverse events associated with a diuretic strategy relying on metolazone or high‐dose loop diuretics. METHODS AN...

Descripción completa

Detalles Bibliográficos
Autores principales: Brisco‐Bacik, Meredith A., ter Maaten, Jozine M., Houser, Steven R., Vedage, Natasha A., Rao, Veena, Ahmad, Tariq, Wilson, F. Perry, Testani, Jeffrey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222930/
https://www.ncbi.nlm.nih.gov/pubmed/30371181
http://dx.doi.org/10.1161/JAHA.118.009149
_version_ 1783369322003955712
author Brisco‐Bacik, Meredith A.
ter Maaten, Jozine M.
Houser, Steven R.
Vedage, Natasha A.
Rao, Veena
Ahmad, Tariq
Wilson, F. Perry
Testani, Jeffrey M.
author_facet Brisco‐Bacik, Meredith A.
ter Maaten, Jozine M.
Houser, Steven R.
Vedage, Natasha A.
Rao, Veena
Ahmad, Tariq
Wilson, F. Perry
Testani, Jeffrey M.
author_sort Brisco‐Bacik, Meredith A.
collection PubMed
description BACKGROUND: In acute decompensated heart failure, guidelines recommend increasing loop diuretic dose or adding a thiazide diuretic when diuresis is inadequate. We set out to determine the adverse events associated with a diuretic strategy relying on metolazone or high‐dose loop diuretics. METHODS AND RESULTS: Patients admitted to 3 hospitals using a common electronic medical record with a heart failure discharge diagnosis who received intravenous loop diuretics were studied in a propensity‐adjusted analysis of all‐cause mortality. Secondary outcomes included hyponatremia (sodium <135 mEq/L), hypokalemia (potassium <3.5 mEq/L) and worsening renal function (a ≥20% decrease in estimated glomerular filtration rate). Of 13 898 admissions, 1048 (7.5%) used adjuvant metolazone. Metolazone was strongly associated with hyponatremia, hypokalemia, and worsening renal function (P<0.0001 for all) with minimal effect attenuation following covariate and propensity adjustment. Metolazone remained associated with increased mortality after multivariate and propensity adjustment (hazard ratio=1.20, 95% confidence interval 1.04–1.39, P=0.01). High‐dose loop diuretics were associated with hypokalemia and hyponatremia (P<0.002) but only worsening renal function retained significance (P<0.001) after propensity adjustment. High‐dose loop diuretics were not associated with reduced survival after multivariate and propensity adjustment (hazard ratio=0.97 per 100 mg of IV furosemide, 95% confidence interval 0.90–1.06, P=0.52). CONCLUSIONS: During acute decompensated heart failure, metolazone was independently associated with hypokalemia, hyponatremia, worsening renal function and increased mortality after controlling for the propensity to receive metolazone and baseline characteristics. However, under the same experimental conditions, high‐dose loop diuretics were not associated with hypokalemia, hyponatremia, or reduced survival. The current findings suggest that until randomized control trial data prove otherwise, uptitration of loop diuretics may be a preferred strategy over routine early addition of thiazide type diuretics when diuresis is inadequate.
format Online
Article
Text
id pubmed-6222930
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62229302018-11-19 Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis Brisco‐Bacik, Meredith A. ter Maaten, Jozine M. Houser, Steven R. Vedage, Natasha A. Rao, Veena Ahmad, Tariq Wilson, F. Perry Testani, Jeffrey M. J Am Heart Assoc Original Research BACKGROUND: In acute decompensated heart failure, guidelines recommend increasing loop diuretic dose or adding a thiazide diuretic when diuresis is inadequate. We set out to determine the adverse events associated with a diuretic strategy relying on metolazone or high‐dose loop diuretics. METHODS AND RESULTS: Patients admitted to 3 hospitals using a common electronic medical record with a heart failure discharge diagnosis who received intravenous loop diuretics were studied in a propensity‐adjusted analysis of all‐cause mortality. Secondary outcomes included hyponatremia (sodium <135 mEq/L), hypokalemia (potassium <3.5 mEq/L) and worsening renal function (a ≥20% decrease in estimated glomerular filtration rate). Of 13 898 admissions, 1048 (7.5%) used adjuvant metolazone. Metolazone was strongly associated with hyponatremia, hypokalemia, and worsening renal function (P<0.0001 for all) with minimal effect attenuation following covariate and propensity adjustment. Metolazone remained associated with increased mortality after multivariate and propensity adjustment (hazard ratio=1.20, 95% confidence interval 1.04–1.39, P=0.01). High‐dose loop diuretics were associated with hypokalemia and hyponatremia (P<0.002) but only worsening renal function retained significance (P<0.001) after propensity adjustment. High‐dose loop diuretics were not associated with reduced survival after multivariate and propensity adjustment (hazard ratio=0.97 per 100 mg of IV furosemide, 95% confidence interval 0.90–1.06, P=0.52). CONCLUSIONS: During acute decompensated heart failure, metolazone was independently associated with hypokalemia, hyponatremia, worsening renal function and increased mortality after controlling for the propensity to receive metolazone and baseline characteristics. However, under the same experimental conditions, high‐dose loop diuretics were not associated with hypokalemia, hyponatremia, or reduced survival. The current findings suggest that until randomized control trial data prove otherwise, uptitration of loop diuretics may be a preferred strategy over routine early addition of thiazide type diuretics when diuresis is inadequate. John Wiley and Sons Inc. 2018-09-08 /pmc/articles/PMC6222930/ /pubmed/30371181 http://dx.doi.org/10.1161/JAHA.118.009149 Text en © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Brisco‐Bacik, Meredith A.
ter Maaten, Jozine M.
Houser, Steven R.
Vedage, Natasha A.
Rao, Veena
Ahmad, Tariq
Wilson, F. Perry
Testani, Jeffrey M.
Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis
title Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis
title_full Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis
title_fullStr Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis
title_full_unstemmed Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis
title_short Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis
title_sort outcomes associated with a strategy of adjuvant metolazone or high‐dose loop diuretics in acute decompensated heart failure: a propensity analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222930/
https://www.ncbi.nlm.nih.gov/pubmed/30371181
http://dx.doi.org/10.1161/JAHA.118.009149
work_keys_str_mv AT briscobacikmereditha outcomesassociatedwithastrategyofadjuvantmetolazoneorhighdoseloopdiureticsinacutedecompensatedheartfailureapropensityanalysis
AT termaatenjozinem outcomesassociatedwithastrategyofadjuvantmetolazoneorhighdoseloopdiureticsinacutedecompensatedheartfailureapropensityanalysis
AT houserstevenr outcomesassociatedwithastrategyofadjuvantmetolazoneorhighdoseloopdiureticsinacutedecompensatedheartfailureapropensityanalysis
AT vedagenatashaa outcomesassociatedwithastrategyofadjuvantmetolazoneorhighdoseloopdiureticsinacutedecompensatedheartfailureapropensityanalysis
AT raoveena outcomesassociatedwithastrategyofadjuvantmetolazoneorhighdoseloopdiureticsinacutedecompensatedheartfailureapropensityanalysis
AT ahmadtariq outcomesassociatedwithastrategyofadjuvantmetolazoneorhighdoseloopdiureticsinacutedecompensatedheartfailureapropensityanalysis
AT wilsonfperry outcomesassociatedwithastrategyofadjuvantmetolazoneorhighdoseloopdiureticsinacutedecompensatedheartfailureapropensityanalysis
AT testanijeffreym outcomesassociatedwithastrategyofadjuvantmetolazoneorhighdoseloopdiureticsinacutedecompensatedheartfailureapropensityanalysis